Send to

Choose Destination
Lancet Respir Med. 2015 Mar;3(3):220-34. doi: 10.1016/S2213-2600(15)00063-6. Epub 2015 Mar 9.

Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.

Author information

Division of Infection and Immunity, University College London and National Institute for Health Research (NIHR) Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK; UNZA-UCLMS Research and Training Project, University Teaching Hospital, Lusaka, Zambia. Electronic address:
Kenya Medical Research Institute, Nairobi, Kenya.
WHO Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione Salvatorie Maugeri, Care and Research Institute, Tradate, Italy.
UNZA-UCLMS Research and Training Project, University Teaching Hospital, Lusaka, Zambia.
National Tuberculosis Programme, Ministry of Community Development, Ministry of Health, Lusaka, Zambia.
European Developing Countries Clinical Trials Partnership, Cape Town, South Africa.
National Institute for Medical Research, Muhumbili, Tanzania.
Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, and German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.
Therapeutic Immunology, Departments of Laboratory Medicine, Karolinska Institutet and Center for Allogeneic Stem Cell Transplantation, CAST, Karolinska Hospital, Stockholm, Sweden.


WHO estimates that 9 million people developed active tuberculosis in 2013 and 1·5 million people died from it. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis continue to spread worldwide with an estimated 480,000 new cases in 2013. Treatment success rates of MDR and XDR tuberculosis are still low and development of new, more effective tuberculosis drugs and adjunct therapies to improve treatment outcomes are urgently needed. Although standard therapy for drug-sensitive tuberculosis is highly effective, shorter, more effective treatment regimens are needed to reduce the burden of infectious cases. We review the latest WHO guidelines and global recommendations for treatment and management of drug-sensitive and drug-resistant tuberculosis, and provide an update on new drug development, results of several phase 2 and phase 3 tuberculosis treatment trials, and other emerging adjunct therapeutic options for MDR and XDR tuberculosis. The use of fluoroquinolone-containing (moxifloxacin and gatifloxacin) regimens have failed to shorten duration of therapy, and the new tuberculosis drug pipeline is sparse. Scale-up of existing interventions with increased investments into tuberculosis health services, development of new antituberculosis drugs, adjunct therapies and vaccines, coupled with visionary political leadership, are still our best chance to change the unacceptable status quo of the tuberculosis situation worldwide and the growing problem of drug-resistant tuberculosis.

Comment in

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center